Frazier Lifesciences (NASDAQ:FLAC) announced this morning that its shareholders have approved its business combination with biotech firm NewAmsterdam Pharma Holding during a special meeting today.
The SPAC disclosed that holders of approximately 32% of FLAC Class A ordinary shares exercised their right to redeem their shares for cash, significantly lower than the average redemption rate for completed deals this year at 83.99%.
Additionally, more than 90% of the votes cast at today’s meeting were cast in favor of the business combination. FLAC shareholders also voted to approve all other proposals.
FLAC now expects to close the deal on November 22, subject to the satisfaction or waiver of customary closing conditions. Upon closing, the ordinary shares and redeemable warrants of the combined company, NewAmsterdam Pharma Company, will be listed on The Nasdaq under the ticker symbols “NAMS” and “NAMSW” respectively, and are anticipated to begin trading on November 23.
The parties initially announced their $326 million combination on July 25, 2022. Netherlands-based NewAmsterdam is developing a range of drugs aimed at reducing patient cholesterol levels suffering from liver, heart and brain disorders.
ADVISORS
- Credit Suisse Securities (USA) LLC is acting as lead PIPE placement agent, financial advisor, and capital markets advisor to FLAC.
- Jefferies LLC is also acting as PIPE placement agents to FLAC and is acting as financial advisor and capital markets advisor to FLAC.
- SVB Securities LLC is also acting as PIPE placement agents to FLAC and is acting as financial advisor and capital markets advisor to the Company.
- William Blair & Company, L.L.C. is also acting as PIPE placement agents to FLAC and is acting as financial advisor and capital markets advisor to FLAC.
- Moelis & Co. is also acting as financial advisor to the Company.
- Covington & Burling LLP is acting as legal counsel to the Company.
- Goodwin Procter LLP is acting as legal counsel to FLAC.
- Kirkland & Ellis LLP is acting as legal counsel to the PIPE placement agents.
Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...
M3-Brigade V (NASDAQ:MBAV) has entered into a definitive agreement to combine with crypto treasury firm ReserveOne, assembling about $1 billion in equity funding. ReserveOne is setting up a diversified Bitcoin and digital asset treasury with a portion of its investments going towards blockchain infrastructure and venture raises. The combined company is expected to trade on...
At the SPAC of Dawn As the SPAC market has warmed in 2025, only 21 of the 70 SPACs (30%) that have IPO’d thus far have overfunded their trusts to draw in investors and none of these funded to more than 101%. By contrast, 87% of 2023 SPACs were overfunded – some to as high...
Emmis Acquisition Corporation (NASDAQ:EMISU) has filed for a $100 million SPAC to take a look at the manufacturing sector after a few unique wrinkles in their IPO process. Initial investors are set to receive one right to a 1/10 share in each unit purchased and the SPAC will have 18 months to complete a business...
Chenghe III (NASDAQ:CHEC.U) has filed for a $110 million SPAC to continue the team’s growing series while turning to a new underwriter. The new SPAC is offering investors a 1/2 warrant in each unit and no overfunding of the trust, but it will need to complete a business combination within 18 months of its IPO...